Theater 150 saved by last-minute donors
UncategorizedOjai’s Theater 150 could breathe a big sigh of relief this week. The small community theater located along Highway 150 recently sent out an e-mail to its supporters asking for desperately needed donations: “We have until Monday, [May 31] to raise a substantial portion of the $140,000 we need to create this new annual festival Read More →
From backstage to boardroom: Region
UncategorizedFor some tri-county businesspeople, the best way to end a long day at the office is to clock out and rock out. With a band, that is. Driven musicians often rise in the business world because they’re used to pushing for perfection when no one’s pushing them, and chasing a dream for pay that ranges Read More →
Cal Poly restarts search for new president
UncategorizedAfter campus visits by the three finalists being considered as the new president of Cal Poly San Luis Obispo, CSU Chancellor Charles B. Reed has recommended that the process start over with a new pool of candidates, Cal Poly announced June 2. The CSU board of trustees has concurred with the chancellor’s recommendation, according to Read More →
Planting seeds in San Luis Obispo: New venture fund looks for student entrepreneurs
TechnologyA tech hub takes the right mix of a great university, eager entrepreneurs and money and mentoring. For a long time, San Luis Obispo County has had plenty of the first two and not enough of the latter. That could change with the establishment of SLO Seed Ventures, a fund built by San Luis Obispo Read More →
Fielding Graduate University outgrows its mansion home
ColumnsThe decision to forge into the future or honor history can be a tough one, especially for a higher education institution. For Fielding Graduate University, it means the decision to stay in a historic Santa Barbara mansion — the university’s home for more than two decades — or to move to a larger, more modern Read More →
Has Amgen solved its conundrum?
ColumnsFor the past decade, the world’s biggest biotechnology company has faced what I have come to call the Amgen conundrum. The company’s revenue and profits keep rising, along with new ways of delivering its core drugs Epogen and Aranesp. But big one ingredient has been missing — a rising share price. After a spectacular rise Read More →
